The Benign Prostatic Hyperplasia Registry and Patient Survey: study design, methods and patient baseline characteristics

  title={The Benign Prostatic Hyperplasia Registry and Patient Survey: study design, methods and patient baseline characteristics},
  author={Claus G. Roehrborn and James G. Nuckolls and J.T. Wei and William D. Steers},
  journal={BJU International},
The first paper describes the design and baseline characteristics of patients in the BPH Registry and Patient Survey in the USA. This important study will provide information on management practices and outcomes of men with this condition, as well as examining the effects of demographics, socio‐economics, comorbidities and medical therapies. 
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
It is hoped the information offered in this guideline document will aid Canadian urologists, as they strive to provide state-of-the-art care to their patients.
Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting
To evaluate the association between the International Prostate Symptom Score (IPSS) bother question (BQ) and a validated disease‐specific quality‐of‐life questionnaire, the Benign Prostatic
The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume
To investigate the potential mechanism of the effect of metabolic syndrome (MetS) on prostate volume (PV) and the risk of benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and
Association of 5α‐reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy
The association of 5α‐reductase inhibitor (5‐ARI) treatment with pathologic and biochemical outcome among the contemporary prostate cancer patients undergoing radical prostatectomy is investigated.
A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction
Tadalafil is today a new treatment alternative to other established drugs for LUTS such as the α-adrenergic antagonists or 5α-reductase inhibitors, however, it is not just an alternative, since sexual adverse events associated with these drugs are avoided and tadalafils is the only drug that can treat both ED and LUTs at the same time.
The Diagnosis and Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia by Primary Care Family Physicians in Portugal
Primary care physicians in Portugal usually diagnose and treat patients with LUTS/BPH rather than refer them to a urologist, and diagnosis and treatment differed for older patients, those with comorbidities and those with more severe nocturia at presentation.
Editorial Comment.
  • N. Davis
  • Medicine
    The Journal of urology
  • 2020
Compared to tissue-necrosing procedures, tissue-eliminating BPH interventions led to lower rates of postoperative urology medication utilization, suggesting that the choice of TUPP may have implications in long-term urologic medication utilization.


AUA guideline on the management of benign prostatic hyperplasia
The development of human benign prostatic hyperplasia with age is studied and correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound is compared.
Office evaluation of men with lower urinary tract symptoms.
Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.
Two measures of disease-specific health status were developed to supplement a symptom score and overall health status measures of benign prostatic hyperplasia, and these measures capture most of the health status significance of BPH symptoms.
Patient Reactions to a Program Designed to Facilitate Patient Participation in Treatment Decisions for Benign Prostatic Hyperplasia
It is suggested that patients can be helped to participate in treatment decisions, and support a randomized trial of the Shared Decisionmaking Program.
International registry results for an interstitial laser BPH treatment device
Initial human use of interstitial thermotherapy is covered, using an 810 nm wavelength diode laser not previously used for such therapy, which is thought to have a reduced risk of death compared to TURP due to significantly reduced bleeding.
[Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging.male (MSAM-7)].
  • R. Rosen, J. Altwein, F. Giuliano
  • Medicine
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
  • 2004
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.